TrialSignal
Clinical trial intelligence report
A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00849524
Status
TERMINATED
Phase
Phase II
Sponsor
Januario Castro, M.D.
Executive brief
Investment-Ready Snapshot
The trial aimed to evaluate the safety and efficacy of Ad-ISF35, a cancer vaccine, administered via intranodal injection in patients with CLL/SLL. The study was conducted at the University of California, San Diego, with a total enrollment of 6 participants.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00849524
Indication
Chronic Lymphocytic Leukemia
Modality
protein therapy
Target
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Intervention
ISF35
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.